Drugs / AV-1451
Trials 2
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1 | NCT03809351 | Jul 2020 → Jul 2028 expected | Alzheimer disease | University of Alabama at Birmingham | Recruiting | No outcome recorded |
| Phase 1 | NCT02736695 | Jul 2016 → Aug 2024 | behavioral variant of frontotemporal dementia, primary progressive aphasia | Mayo Clinic | Completed | No outcome recorded |
Evidence & citations 4 cited values
Every value below carries the sentence it was read from. 2 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | AV-1451 | “No neuroimaging studies have investigated tau deposition in PPA and hence the binding characteristics of AV-1451 (the Tau binding drug used in this study) in PPA are unknown.” NCT02736695 ↗ |
| Known as | F-18 AV 1451 | “Drug: F-18 AV 1451” NCT02736695 ↗ |
| Modality | Diagnostic / imaging agent | “PET imaging agent” NCT03809351 ↗ |
| Route | Intravenous | “given intravenously” NCT03809351 ↗ |